Article Text
A difficult case
Refractory CIDP with chronic lymphocytic leukaemia responding to chemoimmunotherapy
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) has a variable clinical course with 15% remaining refractory to treatment. We report a woman with severe refractory CIDP and coexisting chronic lymphocytic leukaemia (CLL) who improved dramatically after chemoimmunotherapy appropriate for the CLL, including rituximab. A subsequent CIDP relapse after 15 months responded again to similar treatment, and the improvement has been maintained with 3-monthly rituximab infusions as sole ongoing therapy. The case suggests that CIDP refractory to conventional treatment may have associated pathology, in this case haematological malignancy, and that treating the malignancy can effectively treat the CIDP.
- neuroimmunology
- haematology
- neurophysiology
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP
- Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features
- Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy
- Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment
- Treatment of CIDP
- Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy
- Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin
- Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study
- Anti-MAG/SGPG associated neuropathy does not commonly cause distal nerve temporal dispersion
- Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases